GLP-1 diabetes drugs slash dementia risk more than metformin in major study of 174,000 patients
A new study just flipped the script on diabetes treatment. Researchers tracked 174,458 patients with type 2 diabetes and found that GLP-1 receptor agonists cut dementia risk more effectively than metformin. The data spans 20 years. The results aren’t subtle. …